KDR and ovarian cancer: A phase II randomized placebo-controlled study of olaparib in combination with the pan-inhibitors of VEGFR cediranib for the second-line treatment of ovarian cancer showed a significant prolongation of median PFS compared to olaparib alone (17.7 months versus 9.0 months, HR = 2.9, P = 0.001) [11], which is suggested that combined therapy of PARP inhibitors and pan-inhibitors of VEGFR may have synergistic antitumor effect.